| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||
Perspectives |
Author's Affiliation: Department of Medicine and Ireland Cancer Center, Case Western Reserve University School of Medicine and Case Medical Center, Cleveland, Ohio and Howard Hughes Medical Institute, Chevy Chase, Maryland
Requests for reprints: Sanford D. Markowitz, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106. Phone: 216-368-1976; Fax: 216-368-8928; E-mail: sxm10{at}cwru.edu.
The past 10 to 15 years have witnessed major advances in our understanding of polyunsaturated fatty acid metabolism involving synthesis, activity, and degradation of prostaglandin (PG), especially prostaglandin E2 (PGE2), in neoplasia, in particular colorectal neoplasia. Little is known, however, about the role of PG transport in these processes. The flow of PGs in and out of colorectal cells involves highly coordinated activities of PG transporters that become highly dysregulated in colorectal neoplasia. Recent work by various investigators supports key components of this flow for novel molecular-targeted approaches to prevent or treat colorectal neoplasia.
The DuBois lab first reported that cyclooxygenase (COX)-2 is overexpressed in colorectal adenomas and cancer (1), which led to seminal trials of COX-2 inhibitors in familial adenomatous polyposis (2) and sporadic colorectal adenomas (3). This research group and others showed that COX-2–derived PGE2 promotes tumorigenesis by affecting angiogenesis, cell adhesion, invasion, proliferation, and apoptosis (4–9). These effects of COX-2/PGE2 are implemented by PGE2 binding to and activating certain EP receptors and thus activating important pathways including epidermal growth factor receptor, peroxisome proliferator–activated receptor 
, Ras, phosphatidylinositol 3-kinase, and β-catenin signaling. More recent work from this and other groups has shown that 15-hydroxyprostaglandin dehydrogenase (15-PGDH), which degrades intracellular PGE2, was suppressed in colorectal neoplasia from pre-adenoma to invasive stages; suppressed growth of human colorectal cancer cells in immunodeficient mice and inhibited the development of murine intestinal neoplasia when its expression was restored by transfection; and was up-regulated by certain agents including epidermal growth factor receptor and histone deacetylase inhibitors (10–15).
Strong evidence suggests that two cellular transporters of PGE2, the transmembrane influx prostaglandin transporter (PGT) (carrying into the cytoplasm) and efflux multidrug resistance–associated protein (MRP)-4 (carrying out to the extracellular milieu), are deeply implicated in colorectal neoplasia. Although it is the first identified (in 1995) and best studied transporter (16, 17), PGT has not previously been implicated in cancer. Effective termination of PGE2 may require both PGT, which has a high affinity and specificity for PGE2, and 15-PGDH (18). As for MRP4, in noncancer model systems, MRP4 knockout or knockdown led to a pronounced reduction in extracellular PGE2, and MRP4 was inhibited by certain nonsteroidal anti-inflammatory drugs (19, 20); also, MRP4 is overexpressed in colorectal and other cancers (21).
In their exciting new report "Regulation of the Prostaglandin Transporters in Colorectal Neoplasia" in this issue (22), Holla and his colleagues in the DuBois lab build on the foregoing and other related discoveries to address our limited understanding of PGE2 transport and inactivation in neoplasia. They found that PGT was down-regulated in colorectal cancer in the vast majority of their human specimens and cell lines. Although focused on colorectal neoplasia, this study indicated that PGT expression is also dysregulated in stomach, ovary, kidney, and lung cancers. PGT down-regulation occurred early or at the level of adenomas in MIN mice. Forced PGT overexpression in vitro in HCA-7 cells reduced extracellular PGE2 levels and increased intracellular levels of 15-keto PGE2, the catabolic product of PGE2; both events occurred in a dose-dependent fashion, which is consistent with PGT transporting PGE2 into cells and with the known expression of 15-PGDH in HCA-7 cells, which therefore was still available for degrading PGE2 into the Keto product (11). These investigators also showed evidence of epigenetic regulation of PGT by a histone deacetylase inhibitor and a demethylating agent. These PGT results are the first reported for any cancer setting.
These new results of Holla et al. amplify on the known patterns of PG signaling events in colorectal neoplasia. We now can say that colorectal neoplasia throttles down PGT expression in addition to revving up the expressions of COX-2, microsomal PGE synthase 1, and MRP4 and throttling down 15-PGDH (Fig. 1). Data now suggest that cellular efflux of PGE2 in normal cells can occur via two mechanisms, diffusion and MRP transport, whereas PGE2 influx occurs primarily via the PGT. MRP4 seems to increase its efflux role in neoplasia, although diffusion likely continues. This flexibility in efflux suggests that limiting PGE2 influx through reduced PGT may play an important role in up-regulating the effects of the COX-2 pathway in colorectal neoplasia and in producing increased levels of extracellular PGE2 to bind and activate EP receptors. The suggestive timing of these events involves stepwise progressions from early (adenomas) through late stages of colorectal neoplasia.
|
It is clinically important to identify promising non–COX-2 targets within the polyunsaturated fatty acid metabolic signaling pathway (8, 27, 28) because COX-2–selective nonsteroidal anti-inflammatory drugs increased adverse cardiovascular events in long-term prevention trials also showing significant suppression of colorectal neoplasia (3, 29). As indicated in Fig. 1, promising such targets include microsomal PGE synthase 1, EP-2 and EP-4, 15-PGDH, MRP4, and PGT (8–14, 22, 28). Future studies should examine whether the beneficial effects of epigenetic regulation in colorectal neoplasia (27, 30, 31) involve the PG transport–related mechanisms hypothesized above in this article. Mechanistic studies of PGT down-regulation in neoplasia may identify additional new and promising prevention and therapy targets. We look forward to future studies that will assess the functional role of PGT in neoplasia, testing whether restoration of PGT expression suppresses tumorigenesis and elucidating the interactions between PGT and 15-PGDH in antagonizing the activity of the COX-2 oncogenic pathway.
 |
Disclosure of Potential Conflicts of Interest |
|---|
 TOP Disclosure of Potential... References |
|---|
Received for publication January 10, 2007.
Accepted January 14, 2007
|
References |
|---|
|
TOPDisclosure of Potential...References |
|---|
2. Steinbach G, Lynch PM, Phillips RK et al The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946–52.
3. Bertagnolli MM, Eagle CJ, Zauber AG et al Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873–84.
4. Tsujii M DuBois RNAlterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493–501.[CrossRef][Medline]
5. Tsujii M, Kawano S, Tsuji S et al Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705–16.[CrossRef][Medline]
6. Wang D, Wang H, Shi Q et al Prostglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor . Cancer Cell 2004;6:285–95.[CrossRef][Medline]
7. Wang D, Wang H, Guo Y et al Crosstalk between peroxisome proliferator-activated receptor and VEGF stimulates cancer progression. Proc Natl Acad Sci U S A 2006;103:19069–74.
8. Wang D DuBois RNProstaglandins and cancer. Gut 2006;55:115–22.
9. Dannenberg AJ Subbaramaiah KTargeting cyclooxygeanse-2 in human neoplasia: rationale and promise. Cancer Cell 2003;4:431–6.[CrossRef][Medline]
10. Yan M, Rerko RM, Platzer P et al 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-β-induced suppressor of a human gastrointestinal cancers. Proc Natl Acad Sci U S A 2004;101:17468–73.
11. Backlund MG, Mann JR, Holla VR et al 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 2005;280:3217–23.
12. Myung S-J, Rerko RM, Yan M et al 15-Hydroxyprostaglandin dehydrogenase in an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A 2006;103:12098–102.
13. Otani T, Yamaguchi K, Scherl E et al Levels of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-
. Am J Physiol Gastrointest Liver Physiol 2006;290:G361–8.
14. Mann JR, Backlund MG, Buchanan FG et al Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression. Cancer Res 2006;66:6649–56.
15. Tong M, Ding Y, Tai HHHistone deacetylase inhibitors and transforming growth factor-β induce 15-hydroxyprostaglandin dehydrogenase expression in human lung adenomacarcinoma cells. Biochem Pharmacol 2006;72:701–9.[CrossRef][Medline]
16. Kanai N, Lu R, Satriano JA et al Identification and characterization of a prostaglandin transporter. Science 1995;268:866–9.
17. Schuster VLProstaglandin transport. Prostaglandins Other Lipid Mediat 2002;68–9:633–47.
18. Nomura T, Ru L, Pucci ML et al The two-step model of prostaglandin signal termination: in vitro reconstitution with the prostaglandin transporter and prostaglandin 15 dehydrogenase. Mol Pharmacol 2004;65:973–8.
19. Reid G, Wielinga P, Zelcer N et al The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A 2003;100:9244–9.
20. Lin ZP, Zhu Y-L, Johnson DR et al Disruption of cAMP and prostaglandin E2 transport by multidrug resistance protein 4 deficiency alters cAMP-mediated signaling and nociceptive response. Mol Pharmacol 2008;73:243–51.
21. Maubon N, Vee ML, Fossati L et al Analysis of drug transporter expression in human intestinal Caco-2 cells by real-time PCR. Fundam Clin Pharmacol 2007;21:659–63.[CrossRef][Medline]
22. Holla VR, Backlund MG, Yang P, Newman RA, DuBois RNRegulation of prostaglandin transporters in colorectal neoplasia. Cancer Prev Res. In press.
23. De Waart DR, Paulusma CC, Kunne C et al Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int 2006;26:362–8.[CrossRef][Medline]
24. Wolf I, O'Kelly J, Rubinek T et al 15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 2006;66:7818–23.
25. Yang L, Amann JM, Kikuchi T et al Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenease in non-small-cell lung cancer. Cancer Res 2007;67:5587–93.
26. Hazra S, Batra RK, Tai HH et al Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol Pharmacol 2007;71:1715–20.
27. Hsi LC, Xi X, Lotan R et al The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygeanse-1 in colorectal cancer cells. Cancer Res 2004;64:8778–81.
28. Markowitz SDAspirin and colon cancer—targeting prevention? N Engl J Med 2007;356:2195–8.
29. Solomon SD, McMurray JJ, Pfeffer MA et al Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071–80.
30. Suzuki H, Watkins DN, Jair KW et al Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004;36:417–22.[CrossRef][Medline]
31. Yoo CB, Chuang JC, Byun H-M et al Long-term epigenetic therapy with oral zebularine prevents intestinal tumors in mice. Cancer Prev Res. In press.
Key Article
| ||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
, peroxisome proliferator–activated receptor